Breast cancer with neoductgenesis:histopathological criteria and its correlation with mammographic and tumour features by Zhou, Wenjing et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1155/2014/581706
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Zhou, W., Sollie, T., Tot, T., Pinder, S. E., Amini, R-M., Blomqvist, C., ... Wärnberg, F. (2014). Breast cancer with
neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features. Breast
Cancer, 2014, 581706. 10.1155/2014/581706
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
Research Article
Breast Cancer with Neoductgenesis: Histopathological Criteria
and Its Correlation with Mammographic and Tumour Features
Wenjing Zhou,1 Thomas Sollie,2 Tibor Tot,3 Sarah E. Pinder,4
Rose-Marie Amini,5 Carl Blomqvist,6 Marie-Louise Fjällskog,7 Gunilla Christensson,8
Shahin Abdsaleh,7 and Fredrik Wärnberg1,9
1 Department of Surgical Sciences, Uppsala University, 751 85 Uppsala, Sweden
2Department of Pathology, O¨rebro University, 701 85 O¨rebro, Sweden
3Department of Pathology, Falun Central Hospital, 791 82 Falun, Sweden
4Department of Research Oncology, King’s College London, London SE1 9RT, UK
5Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden
6Department of Oncology, Helsinki University Central Hospital, 00029 Helsinki, Finland
7Department of Radiology, Oncology and Radiation Science, Uppsala University, 751 85 Uppsala, Sweden
8Department of Surgery, Falun Central Hospital, 791 82 Falun, Sweden
9Department of Surgery, Uppsala Academic Hospital, 751 85 Uppsala, Sweden
Correspondence should be addressed to Fredrik Wa¨rnberg; fredrik.warnberg@akademiska.se
Received 12 May 2014; Accepted 9 September 2014; Published 8 October 2014
Academic Editor: Zsuzsanna Kaha´n
Copyright © 2014 Wenjing Zhou et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction. Breast cancer with mammographic casting type calcifications, high grade DCIS with an abnormal number of
ducts, periductal desmoplastic reaction, lymphocyte infiltration, and tenascin-C (TN-C) overexpression has been proposed to
represent a more aggressive form of breast cancer and has been denominated as breast cancer with neoductgenesis. We developed
histopathological criteria for neoductgenesis in order to study reproducibility and correlation with other tumourmarkers.Methods.
74 cases of grades 2 and 3 DCIS, with or without an invasive component, were selected. A combined score of the degree(s) of
concentration of ducts, lymphocyte infiltration, and periductal fibrosis was used to classify cases as showing neoductgenesis, or not.
Diagnostic reproducibility, correlation with tumour markers, and mammographic features were studied. Results. Twenty-three of
74 cases were diagnosed with neoductgenesis. The kappa value between pathologists showed moderate reproducibility (0.50) (95%
CI; 0.41–0.60). Neoductgenesis correlated significantly with malignant type microcalcifications and TN-C expression (𝑃 = 0.008
and 0.04) and with ER, PR, and HER2 status (𝑃 < 0.00001 for all three markers). Conclusions. We developed histological criteria
for breast cancer with neoductgenesis. Neoductgenesis, by our applied histopathological definition was related to more aggressive
tumour biology and malignant mammographic calcifications.
1. Introduction
The theory of neoductgenesis in breast cancer was proposed
by La´szlo´ Taba´r, radiologist at the Department of Mammog-
raphy, Falun Central hospital, Sweden [1, 2]. When classi-
fying the mammographic appearance of early stage breast
cancers, Taba´r and coworkers identified a subgroup with
characteristic “casting type” calcifications with or without an
associated tumour mass. The calcifications were present in
large numbers and were unnaturally tightly packed, pointing
in all directions, often filling an entire lobe. The correspond-
ing histopathological picture was described as cancer-filled
duct-like structures associated with periductal lymphocytic
infiltration and a periductal desmoplastic reaction. Taba´r
et al. proposed that this duct-forming process represents
a special type of neoplasia generating a large volume of
neoplastic tissue but not fitting in any classical group of inva-
sive or in situ breast cancer. This group also described how
tenascin-C (TN-C) overexpression was detectable around
the ducts bearing ductal carcinoma in situ of the breast
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(DCIS) in the cases with poor prognosis in their study
[1], indicating an epithelial-stromal interaction similar to
that occurring during the normal development of the duct
system.
DCIS is often detected by breast screening as mammo-
graphic microcalcification without any clinical symptoms.
Preoperative biopsies of cases with overtly malignant micro-
calcification on the mammogram often reveal high grade
DCIS with or without an invasive component [3, 4]. To
distinguish between pure DCIS, which has an excellent
prognosis, and a potentially more aggressive type of breast
cancer with neoductgenesis as proposed by Taba´r et al.
would be of great value. However, we need a more precise
definition of the entity of “neoductgenesis” to be able to test
the reproducibility and then it will be possible to apply these
criteria to patient cohorts and to evaluate the correlation to
prognosis.
In this study, we have defined histopathological criteria
for neoductgenesis, based on the description by Taba´r et al.
In a selected cohort of women with intermediate or high
grade DCIS with or without an invasive component we
applied these criteria to define a group with neoductgenesis
and a group without. Our aim was to evaluate whether the
diagnosis of breast cancerwith neoductgenesis could bemade
in a reproducible way and if so, to study the correlation
between neoductgenesis and mammographic features and
common immunohistochemical (IHC) markers including
TN-C. This study was not designed to study prognosis.
2. Methods
2.1. Patients. Our purpose was to identify a cohort of women
with a substantial number of cases with possible neoductge-
nesis and a control group with breast cancers of the same
type, that is, cases with intermediate or high DCIS with
or without an invasive component but with no signs of
neoductgenesis. The inclusion of cases was based on the
original histopathological report. The original diagnostic
haematoxylin and eosin (H&E) slides were not reviewed in
the process of creating the study cohort.We included primary
tumours but also four recurrences.
Seventy-four women from two different sources were
selected. (A) We prospectively collected tumour tissue from
cases with suspicious mammographic calcifications between
2005 and 2006 at Uppsala Academic Hospital. Of 64 cases,
31 were eligible according to predetermined histopathological
criteria. The remaining 33 cases were either benign lesions
or pure invasive breast cancer and were therefore excluded.
(B) As the prospective collection of cases only resulted in 31
lesions, we also collected cases that were already biobanked
at the pathological departments in Falun and Uppsala. Based
on the original histopathological reports, 11 cases diagnosed
between 1996 and 2002 were selected from the biobank in
Falun and 32 cases diagnosed between 1988 and 2004 from
the biobank inUppsala.TheUppsala cases had been included
in an earlier study [5]. The mammografic apperance was not
evaluated before inclusion in these later 43 cases. The study
was approved by the ethics committee of Uppsala University,
Sweden (Dnr 2005:118 and 2007:315).
2.2. Definition of Neoductgenesis. The definition of neoduct-
genesis by Taba´r and Tot was as follows: “Neoductgenesis
represents abnormal branching of the ducts within a breast
lobe resulting in an unnaturally large number of duct-
like structures per square unit. It is a typical feature of
some high-grade DCIS and is regularly associated with
signs of altered epithelial-stromal interaction, like periductal
lymphocytic infiltration and remodelling of the specialized
periductal stroma.”Thus, the histological criteria included for
evaluation in this study were (1) concentration of duct-like
structures and loss of normal ductal-lobular architecture, as
seen at low power scanning microscopic magnification; (2)
intense periductal lymphocytic infiltration; and (3) fibrosis-
like thickening of the periductal stroma. Taba´r and Tot
also found periductal TN-C accumulation in the cases with
neoductgenesis [2].
In the present study, we quantified the degree of the con-
centration of ducts, lymphocyte infiltration, and periductal
fibrosis as 0, 1, or 2, as per criteria for scoring presented
in Table 1 and Figures 1, 2, and 3. A case with a combined
score of 5 or 6 points was denominated as breast cancer with
neoductgenesis. A case with a combined score of 0 to 4 points
was denominated as a case without neoductgenesis. We did
not include TN-C expression or presence of mammographic
calcification in the definition of neoductgenesis in this study.
Up to five representative slides with tumour tissue from
the original H&E slides from all cases were selected and
then evaluated by four pathologists separately (T Tot, S
Pinder, RM Amini, and H Nordgren) blinded to tumour
biology and follow-up data. In some of the cases just one
slide was available. Scoring of the concentration of duct-like
structures, periductal lymphocytic infiltration, and fibrosis-
like thickening of the periductal stroma was performed and
assigned as 0, 1, or 2 by the different pathologists. In the
analyses comparing cases with neoductgenesis or not we
combined the scoring of all four pathologists and cases
with a score of 17 to 24 points were denominated as breast
cancer with neoductgenesis. Cases scoring 0 to 16 points were
classified as not showing the features of neoductgenesis.
2.3. Mammographic Classification. Mammographic features
were reclassified into six groups as described by Taba´r et al.
[1]: (1) a stellate lesion without associated calcifications; (2)
a circular or oval mass without associated calcifications; (3)
powdery calcifications with or without an associated tumour
mass; (4) casting type calcifications with or without an asso-
ciated tumour mass; (5) crushed stone-like (pleomorphic)
calcifications with or without an associated tumour mass;
and (6) others, that is, galactographic findings or nonspecific
symmetric density.
Mammograms were reviewed by two independent radi-
ologists (Taba´r and Abdsaleh) blinded to tumour biology
and follow-up. Based on the mammographic classification,
all were categorized as being with or without malignant
calcification (4 and 5 versus 1, 2, 3, and 6).
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Table 1: Criteria for scoring the concentration of duct-like structures, lymphocytic infiltration, and periductal fibrosis. The classification of
“neoductgenesis” was based on these histopathological criteria. See Figures 1–3.
Scoring
(1) Concentration of duct-like structures
and loss of normal ductal-lobular
architecture
0 No concentration of duct-like structures and no loss of normalductal-lobular architecture
1 Focal concentration of duct-like structures and focal loss of normalductal-lobular architecture
2 General concentration of duct-like structures and loss of normalductal-lobular architecture
(2) Lymphocytic infiltration
0 No periductal lymphocytic infiltration
1 Mild periductal lymphocytic infiltration
2 Intense periductal lymphocytic infiltration
(3) Fibrosis-like thickening of the
periductal stroma
0 No fibrosis-like thickening of the periductal stroma
1 Little fibrosis-like thickening of the periductal stroma
2 Much fibrosis-like thickening of the periductal stroma
Neoductgenesis Yes 5-6 pointsNo 0–4 points
(a) (b) (c)
Figure 1: Concentration of duct-like structures and loss of normal ductal-lobular architecture. Hematoxylin-eosin stain; microscopic
magnification 20×. (a) No concentration of duct-like structures; (b) focal concentration; (c) general concentration and loss of normal ductal-
lobular architecture.
(a) (b) (c)
Figure 2: Lymphocytic infiltration. Hematoxylin-eosin stain; microscopic magnification 40×. (a) No periductal lymphocytic infiltration; (b)
mild periductal lymphocytic infiltration; (c) intense periductal lymphocytic infiltration.
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(a) (b) (c)
Figure 3: Fibrosis-like thickening of the periductal stroma. Hematoxylin-eosin stain; microscopic magnification 60×. (a) No periductal
fibrosis; (b) little periductal fibrosis; (c) much periductal fibrosis.
(a) (b) (c) (d)
Figure 4: Tenascin-C scoring. Tenascin-C immunostaining; magnification 40×. TMA slide details with tenascin-C expression 0 (a), 1+ (b),
2+ (c), and 3+ (d).
2.4. Tissue Microarray (TMA) and IHC. TMA blocks
were constructed using archival formalin-fixed, paraffin-
embedded specimens. H&E sections were reevaluated and
appropriate tumour areas were selected. Two cores from
the invasive and the in situ components, respectively, with
a diameter of 1.0mm were mounted into the recipient
TMA block using a manual arraying device (MTA-1,
Beecher Inc., WI, USA). The concordance of IHC staining
between biopsies on TMA-slides and original whole section
slides from the same DCIS lesion has previously been
evaluated [6, 7]. We performed IHC for estrogen and
progesterone receptors (ER, PR), HER2, Ki67, and TN-C
on 3.5 𝜇m paraffin sections cut from the TMAs. TMA
slides were immunostained in the Ventana automated
Immunohistochemistry System (Ventana Benchmark
XT and Ultra) using Ventana UltraView DAB (760-500).
IHC was conducted according to established protocols.
Appropriate positive and negative controls were included in
all staining runs. The primary antibody tenascin-C DAKO,
clone TN2, dilution 1 : 50, was used.
Tumours that showed nuclear staining in 10% or more
of the tumour cell nuclei were considered ER and/or PR
positive. This is still used as the clinical cut-off for invasive
breast cancer in Sweden. Using the HerceptTest classification
system, tumours were considered HER2 positive if the score
was 3+ and negative if the score was 0–2+. Ki67 stains were
considered high if staining was seen in more than 20% of
tumour nuclei. The scoring was done by one observer (T
Sollie). The staining intensity of TN-C was assessed in the
periductal area and judged as negative/normal = 0; weak = 1;
moderate = 2; and intense = 3, as presented in Figure 4. TN-
C staining was scored by one pathologist (T Tot) and cases
with moderate or intense staining (2-3) were considered TN-
C positive.
If only one core contained enough tumour tissue, this
was used for classification but at least 200 cells had to be
evaluable. In 51 of the cases, we had sufficient tissue for
TMA construction. IHC data for the remaining 23 cases
were collected from TMAs used in an earlier study or from
original slides if available [8]. We scored the IHC in the
DCIS component in the mixed cases primarily, but in two
cases insufficient tumour material was retrieved from the
DCIS component andweused the invasive cancer component
instead. We have earlier shown that the ER and HER2
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expression in the DCIS and invasive components of mixed
cases correlate significantly [9].
2.5. Statistical Analysis. Fisher’s exact tests were used to
compare the distribution of clinical and histopathological
characteristics of the primary DCIS in those with and those
without neoductgenesis. Pathological scoring data were ana-
lyzed to test the consistency of four independent pathologists
using the Fleiss’s Kappa from rating scores.The interpretation
of the Kappa results followed Shrout’s instructions [10, 11].
3. Results
Baseline characteristics for the 74 cases, 32 with pure DCIS
and 42 with DCIS and an invasive component, are shown in
Table 2. ER and PR status were considered positive in 71.6%
and 56.7% of all cases, respectively. HER2 overexpression
and high proliferation by Ki67 were seen in 39.2% and
29.7%, respectively. Of the 74 cases, 48 showed malignant
calcifications on the mammogram, according to one or
both of the breast radiologists. The kappa value for the
agreement on malignant calcifications versus not between
the two radiologists was 0.77 (95% CI; 0.59–0.94). Of the
48 cases with malignant calcifications, 15 had casting type
calcifications and 19 had crushed stone-like calcifications,
classified as such by both observers. Six cases were classified
as casting type by one radiologist and crushed stone-like
calcifications by the other radiologist, and another six cases
were classified as malignant calcifications by one reader but
not by the other reader. In two cases, mammograms were
not available for review and data was retrieved from the
original report. In 40 of 51 cases successfully stained for
TN-C, staining was classified as high (2-3 points) and the
proportion of stained caseswas similar among pureDCIS and
mixed lesions (50.0% and 57.1%, resp.).
An increased concentration of ducts (1 or 2 points) was
seen in 77.0% of the pure DCIS and in 69.0% of the mixed
cases. Lymphocyte infiltration (1 or 2 points) was found in
59.5% of the pure DCIS and in 69.0% of the mixed cases.
Mild or intense periductal fibrosis was seen in 90.6% of the
pure DCIS and in 88.3% of the mixed cases. The correlation
between each of these three histopathological features and
common tumour markers are presented in Table 3.
Using our definition of neoductgenesis based on the
three histopathological characteristics together, 23 cases were
defined as breast cancer with neoductgenesis and 51 as breast
cancer without neoductgenesis. The kappa value for the
diagnosis of neoductgenesis versus not (5-6 points versus
0–4 points) was 0.50 (95% CI; 0.41–0.60) between the
four pathologists. If we used the histopathological criteria
combined with the mammographic criteria of casting type
calcifications and with an increased TN-C expression, 14
cases were defined as showing neoductgenesis, as three cases
of the 23 showing histopathological signs of neoductgenesis
did not show casting type malignant calcifications, one was
TN-C low, and another five cases had missing TN-C data.
The correlation between tumours with and without
histopathological neoductgenesis and patient and other
tumour markers is presented in Table 4. Age at diagno-
sis did not differ between women with a breast cancer
with features of neoductgenesis and those without. Cases
with neoductgenesis showed malignant calcifications on the
mammograms significantly more often than cases without
neoductgenesis (87.0% versus 54.9%, 𝑃 = 0.008). Among the
23 cases with neoductgenesis, mammographic calcifications
were classified as casting type by both breast radiologists in
ten cases and crushed stone-like in six cases. Also, 23 of the
51 cases with no histopathological signs of neoductgenesis
had malignant calcifications on the mammograms. Tumours
with neoductgenesis were more often of cytonuclear grade
3, (82.6% versus 56.9%, 𝑃 = 0.03). Neoductgenesis was
also statistically significantly correlated with ER negativity
(63.6% versus 8.2%, 𝑃 < 0.00001), PR negativity (81.8 versus
22.4%, 𝑃 < 0.00001), and HER2 positivity (90.5% versus
20.8%, 𝑃 < 0.00001), compared with cases showing no
signs of neoductgenesis. Eighteen cases were classified as
HER2 2+ by IHC. The correlation between HER2 positivity
and neoductgenesis was still statistically significant if these
HER2 2+ cases were considered HER2 positive or if they
were excluded from the analysis. High proliferation was also
seen more often in cases with neoductgenesis, but this was
only of borderline statistical significance (47.6% versus 25.0%,
𝑃 = 0.06). TN-C staining was performed in 51 of the
cases. Seventeen of the 18 cases (94.4%) with neoductgenesis
showed an overexpression of TN-C and 23 of the 33 (69.7%)
cases without neoductgenesis (𝑃 = 0.04).
4. Discussion
A new entity of breast cancer has been proposed: breast
cancer with neoductgenesis, that is, a cancer often described
as “DCIS” which in reality may behave as a duct forming
invasive carcinoma. The original description was based on
a combination of mammographic casting type calcifications,
histopathological features, and TN-C expression. We defined
and quantified the histopathological criteria for the diagnosis
and by using these criteria the diagnosis of breast cancer
with neoductgenesis could be made with moderate repro-
ducibility. In this study, we only used these histopathological
criteria to define neoductgenesis and we excluded mammo-
graphic features and TN-C expression. Instead we evaluated
their correlation with the histopathological criteria. We
also found that neoductgenesis according to our definition
correlated highly with more aggressive tumour biology. This
is potentially valuable in clinical management. As a group,
women with a pure DCIS have an excellent prognosis. If
the histopathological diagnosis of neoductgenesis confers,
or indicates, a poorer prognosis, it would be of value for
treatment decisions, such as whether to perform sentinel
lymph node biopsy, especially if this diagnosis could be made
on preoperative core needle biopsy of patients with DCIS.
The kappa value for the correlation between the four
pathologists was 0.50. This is a moderate agreement accord-
ing to Landis and Koch [12]. Further work is indicated to
tighten the criteria, particularly in relation to any prognostic
value; we believe that larger studies with clinical follow-up
6 International Journal of Breast Cancer
Table 2: Baseline characteristics in 74 women with DCIS with or without an invasive component.
Characteristics All cases (𝑛 = 74) Pure DCIS (𝑛 = 32) DCIS with an invasive component (𝑛 = 42)
Number (%) Number (%) Number (%)
Age at diagnosis
≤55 years 29 (39.2) 14 (43.8) 15 (35.7)
>55 years 45 (60.8) 18 (56.2) 27 (64.3)
Mammographic casting type or crushed
stone-like calcifications
Yes 48 (64.9) 23 (71.9) 25 (59.5)
No 26 (31.1) 9 (28.1) 17 (40.5)
Cytonuclear grade
2 26 (35.1) 7 (21.9) 19 (45.2)
3 48 (64.9) 25 (78.1) 23 (54.8)
ER
Positive 53 (71.6) 22 (68.8) 31 (73.8)
Negative 18 (24.3) 7 (21.9) 11 (26.2)
Missing 3 (4.1) 3 (9.3) 0
PR
Positive 42 (56.7) 18 (56.2) 23 (57.1)
Negative 29 (39.2) 11 (34.4) 16 (47.9)
Missing 3 (4.1) 3 (9.4) 0
HER2
Positive 29 (39.2) 13 (40.6) 16 (38.1)
Negative 40 (54.1) 15 (46.9) 25 (59.5)
Missing 5 (6.8) 4 (12.5) 1 (2.4)
Ki67
High 22 (29.7) 7 (21.9) 15 (35.7)
Low 47 (63.5) 21 (65.6) 26 (61.9)
Missing 5 (6.8) 4 (12.5) 1 (2.4)
Tenascin-C
Positive 40 (54.0) 16 (50.0) 24 (57.1)
Negative 11 (14.9) 5 (15.6) 6 (14.3)
Missing 23 (31.1) 11 (34.4) 12 (28.6)
Concentration of duct-like structures∗
No 17 (23.0) 4 (12.5) 13 (31.0)
Focal 33 (44.6) 15 (46.9) 18 (42.8)
General 24 (32.4) 13 (40.6) 11 (26.2)
Lymphocytic infiltration∗
No 26 (35.1) 13 (40.6) 13 (31.0)
Mild 29 (39.2) 12 (37.5) 17 (40.5)
Intense 19 (25.7) 7 (21.9) 12 (28.5)
Fibrosis-like thickening of the periductal
stroma∗
No 8 (10.8) 3 (9.4) 5 (11.9)
Mild 52 (70.3) 24 (75.0) 28 (66.7)
Intense 14 (18.9) 5 (15.6) 9 (21.4)
Neoductgenesis∗∗
Yes, 17–24 23 (31.1) 9 (28.1) 14 (33.3)
No, 0–16 51 (68.9) 23 (71.9) 28 (66.7)
∗The value is based on the average score among the four pathologists.
∗∗The value is based on the combined scores among the four pathologists.
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Table 4: The correlation between neoductgenesis and patient and
tumour characteristics in 74 cases with intermediate (grade 2) or
high (grade 3) DCIS with or without an invasive component.
Neoductgenesis∗
𝑃 valueYes (𝑛 = 23)
Number (%)
No (𝑛 = 51)
Number (%)
Age at diagnosis
(𝑛 = 74)
≤55 years 10 (43.5) 19 (37.3) 0.61
>55 years 13 (56.5) 32 (62.7)
Mammographic
casting type or
crushed stone-like
calcifications (𝑛 = 74)
Yes 20 (87.0) 28 (54.9) 0.008
No 3 (13.0) 23 (45.1)
DCIS with or without
an invasive
component (𝑛 = 74)
DCIS 9 (39.1) 23 (45.1) 0.63
DCIS + invasive 14 (60.9) 28 (54.9)
Cytonuclear grade
(𝑛 = 74)
2 4 (17.4) 22 (43.1) 0.03
3 19 (82.6) 29 (56.9)
ER (𝑛 = 71)
Positive 8 (36.4) 45 (91.8)
<0.001
Negative 14 (63.6) 4 (8.2)
PR (𝑛 = 71)
Positive 4 (18.2) 38 (77.6)
<0.001
Negative 18 (81.8) 11 (22.4)
HER2 (𝑛 = 69)
Positive 19 (90.5) 10 (20.8)
<0.001
Negative 2 (9.5) 38 (79.2)
Ki67 (𝑛 = 69)
High 10 (47.6) 12 (25.0) 0.06
Low 11 (52.4) 36 (75.0)
Tenascin-C (𝑛 = 51)
Positive 17 (94.4) 23 (69.7) 0.04
Negative 1 (5.6) 10 (30.3)
∗Neoductgenesis was defined as a total score of 17–24 between four pathol-
ogists, combining the scores for concentration of ducts (0–2), lymphocytic
infiltration (0–2), and periductal fibrosis (0–2) for each pathologist.
data are indicated. One potential explanation of this Kappa
value could be that in many cases only one or two sections
from each lesion were available for the pathologists. Some
of the lesions were small and we had problems finding
representative slides for all cases. The correlation should be
better in a clinical setting where more representative tumour
tissue will be available and when histological large sections
can be used [13]. We look at this study as a first step trying to
define neoductgenesis and we are well aware that the system
may have to be improved.
In addition, the number of cases in this study was
relatively low and they were selected from different sources
and time periods and, furthermore, both pure DCIS and
DCIS with an invasive component and recurrences were
included. Also, different treatments were given. This makes
any study of the relation to prognosis impossible. Instead,
our aim was to create a study cohort enriched with cases of
possible neoductgenesis and a comparable groupwith similar
tumour characteristics except for neoductgenesis. We believe
wemanaged to do this, but the next step will be a larger study
in a less selected patient cohort where we also can relate our
histopathological criteria to prognosis. An indication of that
the entity of neoductgenesis might have a poorer prognosis
was published on a consecutive material of 108 DCIS cases,
reported earlier by Tot [13].
We also wish to study the biology behind the proposed
entity of neoductgenesis. We do not have any evidence of the
actual formation of new ducts but this has been proposed
as the mechanism. Actually, of the features included in our
definition of neoductgenesis in this study the presence of
“concentration of duct-like structures and loss of normal
ductal-lobular architecture” showed the weakest correlation
withmammographic calcification and histological features of
aggressiveness.
All three histopathological features: concentration of
duct-like structures and loss of normal ductal-lobular archi-
tecture, intense periductal lymphocytic infiltration, and
fibrosis-like thickening of the periductal stroma, correlated
with cytonuclear grade and ER, PR, and HER2 expression to
some degree. In a report from 2009 [14] by Chivukula et al. on
preoperative core needle biopsies, regressive changes in high
grade DCIS including periductal fibrosis and inflammation
correlated with invasive cancer in the surgical specimen
and axillary node metastasis. However, no correlation was
studied between these regressive changes and other tumour
markers, concentration of ducts, or mammographic features.
In our study, lymphocytic infiltration and periductal fibro-
sis showed the strongest association with the histological
features of aggressiveness and mammographic calcifications,
while this association was weaker for concentration of duct-
like structures. Interestingly, a strong association between
chronic inflammation and cytonuclear grade as well as risk
of local invasive recurrence in DCIS has recently been shown
[15]. Furthermore, combining the three histopathological
features, as in cases with neoductgenesis, resulted in a highly
statistically significant association with the IHC markers.
The association with HER2 expression was especially
noteworthy. The lesions that were not classified as showing
neoductgenesis were HER2 positive in only 21% of the cases,
while breast cancers with neoductgenesis wereHER2 positive
in approximately 90%. Neoductgenesis may thus be related to
the HER2 positive molecular subgroup (HER2+/ER−/PR−)
[16] and it would be interesting to study the gene expression
of these lesions and also, data on HER2 amplification would
strengthen the analyses. In invasive breast cancer the HER2
positive subgroup has been shown to be related to poor
prognosis [17–19]. However, this is not very well studied in
pure DCIS; we have seen indications of this being true also
for in situ lesions [8].
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It could be argued that the proposed entity of DCIS with
neoductgenesis is similar to high grade, HER2 positive DCIS.
Among the 32 pure DCIS cases in this study, nine were
classified as DCIS with neoductgenesis and all the nine cases
were high grade and seven out of eight cases with HER2 data
were HER2 positive. On the other hand, six of the 13 high
grade, HER2 positive DCIS were not classified as DCIS with
neoductgenesis by the pathologists. Of all 74 cases, 28 were
high grade and were HER2 positive. Of these 28, 10 were not
classified as breast cancer with neoductgenesis.
In a clinical setting the mammographic picture may
suggest before surgery whether the patient has a lesion
with features of neoductgenesis. A preoperative core needle
biopsy is typically performed for diagnosis; the usefulness
of adapting the histopathological criteria described in the
assessment of large needle biopsies has to be evaluated
if there are implications for choice of surgical treatment.
Again, the criteria for diagnosis, even if proven of value and
reproducibility in whole sections, may have to be adapted for
application to core biopsy samples.
In this study we did not include the mammographic
features in the definition of neoductgenesis. Rather, we
studied the correlation between the histopathology and the
mammographic features and report a statistically significant
correlation between histopathological neoductgenesis and
malignant calcifications (casting type and/or crushed stone-
like calcifications). However, many of the cases with no signs
of neoductgenesis also presented with malignant microcalci-
fications on the mammograms.
TN-C is an extracellular glycoprotein involved in tissue
interactions during embryogenesis (e.g., ductgenesis in the
normal breast), wound healing, inflammation, and malig-
nancy. TN-C is expressed by normal mesenchymal and
epithelial cells as well as by some cancer cells. The charac-
teristics of TN-C include antiadhesion effects and growth
promotion by increasing the mitogenic effect of fibroblast
growth factor and are a prerequisite for epidermal growth
factor-induced proliferation [20, 21]. This suggests an impor-
tant role for TN-C in tumour-matrix interactions, potentially
regulating tumour proliferation, invasion, and metastasis.
Loss of epithelialmorphology and gain ofmesenchymal char-
acteristics may be seen in cancer cells in tumour progression
[20]. TN-C has also been regarded as a potential marker for
microinvasion in DCIS by some authors [22–25]. In a study
by Jahkola et al., the prevalence of periductal TN-C staining
in DCIS correlated with high grade, high proliferation, and
PR negativity as well as microinvasion [20]. The reason not
to include TN-C in our definition of neoductgenesis in this
study was partly based pragmatically on the fact that we did
not succeed with the assessment of expression of TN-C in
more than 51 of the 74 cases. Subsequently, almost all cases
showing neoductgenesis stained positively for TN-C (17/18)
but, in parallel with malignant calcifications, nearly 70% of
the cases without neoductgenesis also showed overexpression
of TN-C in this highly selected study. We selected about
half of the cases based on mammographic appearance and
we also only included cases of intermediate or high grade
DCIS. Despite this bias, we found a statistically significant
correlation between our definition of neoductgenesis and
TN-C expression. This also requires further assessment in
larger series.
In conclusion, we have developed histological criteria
for a proposed new entity of breast cancer: breast cancer
with neoductgenesis. Neoductgenesis, by our definition, was
related to more aggressive tumour biology, especially HER2
positivity and to mammographic calcifications. The number
of cases is relatively small, there is case selection bias, and the
results require validation.The biology behind the histopatho-
logical features and its potential relation to prognosis also
needs to be further studied.
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